Provides patient management software to identify and track patients. Offers financial accounting software for business office applications. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 5% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $20.1M would still be left in the vault — a solid cushion for hard times.
The market pays 30.7× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $24.9M in the vault; even if every debt were paid off, $20.1M would remain.
Over the last 12 months, company executives reported 17 buys and 3 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.40 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back.
Costs swallow the gains that sales growth brings in.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.